Skip to main content

Weather Alert

Hurricane activity is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide
Quest Diagnostics

Signatures of Disease and Resistance: FLT3 in Review

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: Signatures of Disease and Resistance: FLT3 in Review

Authors: Grubbs C, Ma C, Ulrich M,Allen D, Cronin NL, Escalada S, Godsey JH, Gonong B, Hochstein P, Le A, Nguyen T, Racke FK, Utulo S, Van Ness ME

Specialty: Oncology, Hematology

Related content

On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
Conference Presentation
A novel highly sensitive approach for residual disease detection in AML using digital PCR
Test FAQ
AML Rapid Mutation Panel
Test FAQ
FLT3 Mutation Analysis
Test FAQ
Isocitrate Dehydrogenase 1 and 2 (IDH1/IDH2) Mutation Analysis (IDH1 and IDH2 Mutation)
Publication
Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases
Publication
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation
Audio Podcast
Optimize Oncology Care with Clinical Pathways

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.